Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy

JAMA

Volumn 287, Issue 13, 2002, Pages 1690-1698

  Higashi, Mitchell K ^a   Veenstra, David L ^a   Midori Kondo, L ^a   Wittkowsky, Ann K ^a   Srinouanprachanh, Sengkeo L ^a   Farin, Fred M ^a   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C9; WARFARIN;

ADULT; AGED; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; DISEASE ASSOCIATION; DRUG INDICATION; DRUG METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; INTERNATIONAL STANDARD UNIT; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK;

EID: 0037012465     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.287.13.1690     Document Type: Article

References (37)

1. Oral anticoagulants
2. A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin
3. Allelic variants of human cytochrome P4502C9
4. Genetic analysis of the human cytochrome P450 CYP2C9 locus
5. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism
6. Genetic polymorphism of CYP2C9 and its effect on warfarin maintenance dose requirement in patients undergoing anticoagulation therapy
7. Metabolism of warfarin enantiomers in Japanese patients with heart disease having different CYP2C9 and CYP2C19 genotypes
8. Comparisons between in-vitro and in-vivo metabolism of (S)-warfarin
9. Chiral phase analysis of warfarin enantiomers in patient plasma in relation to CYP2C9 genotype
10. Hydroxylation of warfarin by human cDNA-expressed cytochrome P450
11. The R144C change in the CYP2C9* 2 allele alters interaction of the cytochrome P450 with NADPH: Cytochrome P450 oxidoreductase
12. CYP2C9 Ile359 and Leu359 variants
13. Validation of methods for CYP2C9 genotyping
14. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
15. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
16. Interindividual variability in sensitivity to warfarin - Nature or nurture?
17. Comparison of 5-mgand 10-mg loading doses in initiation of warfarin therapy
18. Thrombosis
19. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia
20. Risk factors for complications of chronic anticoagulation
21. Genetic analysis of CYP2C9 polymorphism in a Japanese population
22. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population
23. Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans
24. Bleeding complications in oral anticoagulant therapy
25. Assessing random error in the international normalized ratio
26. Risk factors for intracranial hemorrhage in outpatients taking warfarin
27. Recurrent event models
28. Cox's method for follow-up studies
29. The Hardy-Weinberg principle
30. Statistical inference from genetic data on pedigrees
31. The risk for and severity of bleeding complications in elderly patients treated with warfarin
32. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation
33. Assessing the cost-effectiveness of pharmacogenomics
34. Potential role of pharmacogenomics in reducing adverse drug reactions
35. New anticoagulants
36. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients